A Phase 1 interventional study of Tocilizumab in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 35 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-14.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 10th largest by enrollment, is one of 5 that started in 2013, is one of 4 in phase 1, and was the 15th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 12 · Phase 4 2
First in 2004; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is close to the median of 52 across 230 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 52 across the 21 interventional studies. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 7 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
17 studies in Arthritis, Juvenile by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Arthritis, Juvenile by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2013, is one of 4 in phase 1, and was the 13th registered.
Hoffmann-La Roche’s Arthritis, Juvenile studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 17 in Arthritis, Juvenile:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with body weight less than (\<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
Drug: Tocilizumab
Participants with body weight greater than or equal to (\>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
Drug: Tocilizumab
Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
Also known as: RoActemra/Actemra
Minimum Serum Concentration (Cmin) of TCZ at Steady State
Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, 2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.
Time frame: Pre-dose (Hour 0) up to 2520 hours post Day 1 dose (detailed timeframe is provided in outcome description section)
Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment
Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016 hours post Day 1 dose (additionally at 6, 12, 48, 120 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016 post Day 1 dose.
Time frame: Pre-dose (Hour 0) up to 2016 hours post Day 1 dose (detailed timeframe is provided in outcome description section)
Maximum Serum Concentration (Cmax) of TCZ at Steady State
Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, ,2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.
Time frame: Pre-dose (Hour 0) up to 2520 hours post Day 1 dose (detailed timeframe is provided in outcome description section)
Change From Baseline in Serum Interleukin-6 (IL-6) Levels
IL-6 is a cytokine associated with disease activity in juvenile idiopathic arthritis (JIA) including the polyarticular juvenile idiopathic arthritis (pJIA) subset. It is found in high levels in the synovial fluid and is associated with indicators of inflammatory activity.
Time frame: Baseline, Days 0.25, 0.5, 2, 4, 5, 84.25, 84.5, 85, 86, 88, 90; Weeks 2, 3, 4, 6, 12, 14, 15, 27, 28, 36, 44, 52
Change From Baseline in Soluble IL-6 Receptor Levels
Time frame: Baseline, Days 0.25, 0.5, 2, 4, 5, 84.25, 84.5, 85, 86, 88, 90; Weeks 2, 3, 4, 6, 12, 14, 15, 27, 28, 36, 44, 52
Change From Baseline in C-Reactive Protein (CRP) Levels
Time frame: Baseline, Weeks 4, 6, 9, 12,18, 20, 27, 28, 36, 44, 45, 51, 52
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
The ESR is an acute phase reactant and a measure of inflammation. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 4, 6, 9, 12, 18, 20, 27, 28, 36, 44, 45, 51, 52
Percentage of Participants With Anti-TCZ Antibodies of Neutralizing Potential
Time frame: Baseline up to Week 52
A total of 52 participants were enrolled in the study. Study included a 21-day screening period.
| Milestone | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Started | 27 | 25 |
| Completed | 24 | 22 |
| Not completed | 3 | 3 |
| Withdrew: Lack of efficacy | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, 2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.
| Micrograms/milliliter (mcg/mL) | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Minimum Serum Concentration (Cmin) of TCZ at Steady State | 13.35 (0.21 to 52.25) | 12.71 (0.19 to 23.75) |
Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016 hours post Day 1 dose (additionally at 6, 12, 48, 120 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016 post Day 1 dose.
| mcg*day/mL | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment | 2998 (1465 to 7708) | 1933 (324 to 3098) |
Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, ,2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.
| mcg/mL | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Maximum Serum Concentration (Cmax) of TCZ at Steady State | 62.44 (39.37 to 121.13) | 29.74 (7.56 to 50.3) |
IL-6 is a cytokine associated with disease activity in juvenile idiopathic arthritis (JIA) including the polyarticular juvenile idiopathic arthritis (pJIA) subset. It is found in high levels in the synovial fluid and is associated with indicators of inflammatory activity.
| picograms/milliliter (pg/mL) | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Baseline | 77.569 ± 278.376 | 10.567 ± 11.24 |
| Day 0.25 | -15.309 ± 108.157 | 4.575 ± 7.555 |
| Day 0.5 | -16.181 ± 116.587 | 11.932 ± 13.33 |
| Day 2 | 17.998 ± 157.295 | 23.223 ± 23.935 |
| Day 5 | 17.265 ± 186.212 | 35.263 ± 64.907 |
| Week 2 | — | 21.751 ± 49.964 |
| Week 3 | -12.801 ± 198.038 | — |
| Week 4 | — | 15.944 ± 26.322 |
| Week 6 | -0.412 ± 271.409 | 17.841 ± 34.515 |
| Week 12 | -45.569 ± 294.169 | 17.236 ± 28.727 |
| Day 84.25 | 32.644 ± 65.094 | 14.66 ± 24.026 |
| Day 84.5 | -46.575 ± 318.217 | 24.478 ± 31.747 |
| Day 85 | — | 27.934 ± 53.23 |
| Day 86 | -53.35 ± 285.831 | 36.06 ± 82.547 |
| Day 88 | -42.836 ± 280.041 | 19.397 ± 22.712 |
| Day 90 | -51.899 ± 299.59 | 20.642 ± 20.247 |
| Week 14 | — | 11.958 ± 16.665 |
| Week 15 | -21.565 ± 312.758 | 122.88 |
| Week 27 | -16.408 ± 293.156 | — |
| Week 28 | — | 14.206 ± 20.762 |
| Week 36 | -38.921 ± 303.851 | 13.273 ± 24.814 |
| Week 44 | — | 14.765 ± 18.458 |
| Week 52 | -44.611 ± 289.698 | 10.401 ± 18.455 |
| nanograms per milliliter (ng/mL) | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Baseline | 140.4 ± 225.72 | 206.7 ± 241.69 |
| Day 0.25 | -4.04 ± 41.14 | 1.78 ± 29.68 |
| Day 0.5 | -1.45 ± 53.39 | 4.58 ± 51.71 |
| Day 2 | 89.72 ± 75.29 | 68.90 ± 66.75 |
| Day 4 | 323.4 ± NA | — |
| Day 5 | 194.46 ± 143.28 | 124.65 ± 100.58 |
| Week 2 | — | 193.25 ± 158.69 |
| Week 3 | 418.54 ± 237.02 | — |
| Week 4 | — | 239.86 ± 194.47 |
| Week 6 | 407.36 ± 344.44 | 233.82 ± 234.92 |
| Week 12 | 464.77 ± 317.77 | 286.06 ± 260.33 |
| Day 84.25 | 461.85 ± 280.99 | 245.05 ± 253.45 |
| Day 84.5 | 482.55 ± 299.43 | 274.85 ± 230.86 |
| Day 85 | — | 268.72 ± 254.46 |
| Day 86 | 461.19 ± 345.97 | 244.53 ± 257.08 |
| Day 88 | 514.89 ± 303.29 | 256.47 ± 234.7 |
| Day 90 | 494.05 ± 276.35 | 292.29 ± 229.2 |
| Week 14 | — | 272.93 ± 241.9 |
| Week 15 | 497.21 ± 295.29 | 200 ± NA |
| Week 27 | 532.81 ± 270.07 | — |
| Week 28 | — | 295.28 ± 286.78 |
| Week 36 | 416.02 ± 305.07 | 269.32 ± 276.03 |
| Week 44 | — | 243.93 ± 299.72 |
| Week 52 | 470.6 ± 263.38 | 209.51 ± 318.38 |
| mg/L | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Baseline | 3.391 ± 5.27 | 3.356 ± 6.908 |
| Week 4 | — | -2.187 ± 5.270 |
| Week 6 | -3 ± 5.21 | -2.368 ± 5.735 |
| Week 9 | -3.069 ± 5.346 | — |
| Week 12 | -3.16 ± 5.285 | -1.783 ± 4.559 |
| Week 18 | -3.213 ± 5.377 | — |
| Week 20 | — | -1.336 ± 6.158 |
| Week 27 | -3.122 ± 5.279 | — |
| Week 28 | — | -2.467 ± 6.455 |
| Week 36 | -3.254 ± 5.492 | -2.209 ± 5.316 |
| Week 44 | — | -2.039 ± 5.47 |
| Week 45 | -3.153 ± 5.385 | — |
| Week 51 | -3.344 ± 5.453 | — |
| Week 52 | — | -2.225 ± 5.285 |
The ESR is an acute phase reactant and a measure of inflammation. A negative change from baseline indicates improvement.
| millimeters per hour (mm/h) | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Baseline | 15.9 ± 14.2 | 13 ± 13.1 |
| Week 4 | — | -7.0 ± 9 |
| Week 6 | -10.6 ± 12.8 | -7.2 ± 10.5 |
| Week 9 | -9.9 ± 10.9 | — |
| Week 12 | -9.8 ± 12.4 | -6.8 ± 13 |
| Week 18 | -11.8 ± 12.3 | — |
| Week 20 | — | -7.9 ± 11.2 |
| Week 27 | -11.9 ± 12.2 | — |
| Week 28 | — | -8 ± 14.2 |
| Week 36 | -11.8 ± 12.8 | -8 ± 13.1 |
| Week 44 | — | -10.2 ± 13 |
| Week 45 | -12 ± 12.2 | — |
| Week 51 | -12.2 ± 13 | — |
| Week 52 | — | -8.5 ± 13.2 |
| percentage of participants | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| Percentage of Participants With Anti-TCZ Antibodies of Neutralizing Potential | 3.7 | 8.0 |
Collected over Baseline up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TCZ SC 162 mg Q3W | — | 1/27 (3.7%) | 23/27 (85.2%) |
| TCZ SC 162 mg Q2W | — | 2/25 (8%) | 22/25 (88%) |
| Event | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/27 | 1/25 |
| Decreased appetiteMetabolism and nutrition disorders | 0/27 | 1/25 |
| Croup infectiousInfections and infestations | 1/27 | 0/25 |
| VaricellaInfections and infestations | 1/27 | 0/25 |
| Event | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W |
|---|---|---|
| NasophryngitisInfections and infestations | 11/27 | 7/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/27 | 3/25 |
| Injection Site ErythemaGeneral disorders | 4/27 | 6/25 |
| HeadacheNervous system disorders | 1/27 | 6/25 |
| NauseaGastrointestinal disorders | 1/27 | 5/25 |
| VomitingGastrointestinal disorders | 4/27 | 5/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/27 | 4/25 |
| DiarrhoeaGastrointestinal disorders | 1/27 | 4/25 |
| PyrexiaGeneral disorders | 2/27 | 4/25 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/27 | 4/25 |
Safety population included all participants who received at least one dose of treatment and who had at least one post-dose safety assessment.
| Age, Continuous(years) | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W | Total |
|---|---|---|---|
| Mean | 5.5 ± 2.1 | 13.9 ± 2.7 | 9.6 ± 4.9 |
| Sex: Female, Male(Participants) | TCZ SC 162 mg Q3W | TCZ SC 162 mg Q2W | Total |
|---|---|---|---|
| Female | 18 | 18 | 36 |
| Male | 9 | 7 | 16 |
The record gives a start of Jul 2013, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab